Screener
Bioventus BVS CapEx
CapEx at other companies
Other financials
Where this comes from
Reported directly by Bioventus in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Bioventus’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:43 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001665988-26-000042
| Line item | Six Months Ended / June 27, 2026 | Six Months Ended / June 28, 2025 |
|---|---|---|
| Net cash from operating activities | 28,807 | 6,607 |
| Investing activities: | ||
| Settlement from the sale of a business | — | (686) |
| Purchase of property and equipment | (1,534) | (1,509) |
| Purchase of equity securities | (1,500) | — |
| Net cash from investing activities | (3,034) | (2,195) |
| Financing activities: | ||
| Proceeds from issuance of Class A common stock | 973 | 1,467 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Bioventus's capex?
- Bioventus (BVS) reported capex of $960K in Q2 2026.
- How has Bioventus's capex changed year-over-year?
- Bioventus's capex increased by 40.6% year-over-year, from $683K to $960K.
- What is the long-term trend for Bioventus's capex?
- Over 3 years (2021 to 2025), Bioventus's capex has grown at a -42.6% compound annual growth rate (CAGR), from $13.52M to $2.56M.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Bioventus's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude